Latest news with #Jeito
Yahoo
21-05-2025
- Business
- Yahoo
Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women's Health
Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women's Health Proceeds from the financing will advance ReproNovo's lead candidates RPN-001 (leflutrozole) and RPN-002 (nolasiban), through Phase 2 clinical trials in male infertility and in the treatment of adenomyosis and embryo implantation, respectively In the context of increasing infertility across the world, this investment reflects Jeito's interest in highly promising clinical-stage biopharma companies developing breakthrough innovations with strong value-creation potential for patients and society Paris, France, May 21, 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today it is leading a USD 65 million (EUR 57 million1) Series A financing round in ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women's health. AXA IM Alts and M Ventures co-led the financing round alongside a syndicate of healthcare funds: Ysios Capital and ALSA Ventures. Ksenija Pavletic, Jeito Partner and Chief Commercial Officer with 25 years of experience in reproductive medicine and women's health, will join ReproNovo's Board of Directors. Founded in 2021, ReproNovo is developing novel approaches to address critical gaps in reproductive medicine and women's health, including male and female infertility as well as uterine health. The company, led by a team of experts in this space – Jean Marie Duvall, Chief Executive Officer, Joan-Carles Arce, MD, PhD, Chief Scientific Officer and Medical Officer, and BingMei Hao, Chief Financial Officer – brings a proven track record in successful clinical development and commercial launches. Since its inception, ReproNovo has rapidly built a pipeline comprising two Phase 2 clinical-stage assets across three disease areas, and the company plans to use the proceeds from this financing to advance this pipeline across multiple programs: With its lead candidate, RPN-001 (leflutrozole), the company will focus on the development of an oral therapy for male infertility due to low testosterone levels. Low testosterone is becoming more prevalent, including in younger men, highlighting the urgent need for an efficacious treatment option. This trend coincides with a broader decline in male reproductive health, now recognized as a major public health problem2. RPN-002 (nolasiban), also orally administered therapy, is a first-in-class compound to manage adenomyosis, an overgrowth of endometrial tissue into the uterus that can result in severe menstrual bleeding and pain. Similar to endometriosis, this is a common gynecological condition, with recent imaging studies identifying features of adenomyosis in nearly one in four women undergoing gynecological evaluation3. RPN-002 will also be explored for improving success rates in assisted reproductive technologies (ART). The global decline in fertility rates, coupled with the rising incidence of male infertility (sperm counts have fallen by 50% to 60% over the last four decades4) and the significant health risks women endure during fertility treatments underscore the urgent and underserved need for innovative reproductive solutions that address both genders and these global challenges comprehensively. Through this investment, Jeito reaffirms its commitment to highly promising companies with transformational science that has the potential to deliver strong value for patients and society. By tackling male infertility and women's health at a global scale, ReproNovo is addressing not only a significant patients' concern but also a major societal issue. Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: 'ReproNovo combines strong innovative potential, a seasoned team, and a clear ambition to address one of the most pressing global challenges of our time: declining birth rates. At Jeito, we are committed to advancing breakthrough innovations with significant value for both patients and society. This investment reflects that commitment. We are proud to support the acceleration of ReproNovo's clinical development and help unlock its potential to become a future market leader.'Ksenija Pavletic, Partner and Chief Commercial Officer at Jeito Capital, added: 'As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients. We are highly impressed by the ReproNovo team, whose members have a strong track record in this field, having brought a number of compounds successfully through clinical development and onto the market. Their deep understanding of the field will enable them to effectively address critical unmet needs that have a strong impact on society.' Jean Marie Duvall, Co-founder and CEO of ReproNovo, concluded: 'We are focused on innovative therapeutic solutions for male and female infertility and pioneering management options for conditions like adenomyosis. Our aim is to address critical gaps in the landscape of infertility and women's health worldwide. We are thrilled to announce the successful closing of our $65 million Series A funding round with this strong, sector specialized group of investors, marking a significant milestone in our journey to becoming a leading reproductive medicine and women's health company.' About Jeito CapitalJeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito has built a diversified portfolio of clinical biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United more information, please visit or follow us on LinkedIn. About ReproNovo ReproNovo is a cutting-edge biopharmaceutical company identifying and developing innovative solutions to address critical gaps in reproductive medicine and women's health. Our team is composed of proven experts with deep experience in reproductive medicine, drug development, regulatory affairs and business development who have throughout their careers successfully brought multiple therapies to market. Lead clinical compound, RPN-001 (leflutrozole), is initially being developed to treat male infertility. RPN-002 (nolasiban) is a first-in-disease and first-in-class molecular entity to manage adenomyosis and increase the probability of embryo implantation in women undergoing assisted reproductive technology (ART) treatments. Both assets are Phase 2 ready. ReproNovo is financed by Jeito Capital, AXA IM Alts, founding investor M Ventures, Ysios Capital and ALSA Ventures. Headquartered in Lausanne, Switzerland, the company has its primary development team in Copenhagen, Denmark, and an additional development site in Barcelona, Spain. For more information, visit the Company's website at Contacts: Jeito Capital Rafaèle Tordjman, Founder & CEOJessica Fadel, EATel: +33 6 33 44 25 47 Maior ICR HealthcareStéphanie Elbaz Mary-Jane Elliott / Davide Salvi / Kris LamTel: +33 6 46 05 08 07 Jeito@ +44 (0) 20 3709 5700 Sean Leous Tel: +1 (646) 866 4012 1 EUR/USD exchange rate: 1 EUR = 1.1343 USD date May 5, 2025 (source: Banque de France)2 Temporal trends in sperm count: a systematic review and meta-regression analysis of samples collected globally in the 20th and 21st centuries. Human Reproduction Update. 2022; Alson S, et al. Prevalence of adenomyosis features in women scheduled for assisted reproductive treatment, using the Morphological Uterus Sonographic Assessment (MUSA) group definitions. Acta Obstet Gynecol Scand. 2024;103:1142–1152.4 Fortune 'The global 'spermpocalypse' proves infertility is no longer just a women's problem, says male fertility CEO' (May 2024)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C disease and GM1/GM2 gangliosidoses, three forms of rare lysosomal storage disorders, as well as expanding Azafaros pipeline to other indications The patient benefit drives Jeito's mission. This investment in life threatening rare genetic disorders, affecting children and young adults illustrates Jeito's commitment to accelerate the development of high-impact treatments for patients with high unmet needs Paris, France, May 13, 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announces today it is leading an oversubscribed EUR 132 million Series B financing round in Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders. The financing is led by Jeito Capital, and co-led by Forbion Growth, with participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures. Rachel Mears, Partner, and Julien Elric, Senior Principal at Jeito Capital will join Azafaros's Board of Directors as Board members. Founded in 2018 and built on scientific discoveries from Leiden University and Amsterdam University Medical Center (UMC), Azafaros is led by a seasoned team of experts in rare disease drug development and commercialization. The company is developing a first-in-class dual-acting drug candidate to offer new treatment options to patients with lysosomal storage disorders, a group of severe rare genetic diseases that often cause progressive neurodegeneration and, in many cases, fatal outcomes. Its lead asset, nizubaglustat, has been awarded Orphan Drug Designation in both the US and Europe as well as Fast track status in the US. The financing will advance two Phase 3 programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) disease and GM1/GM2 gangliosidoses as well as expanding Azafaros pipeline to other indications. The company expects to initiate both Phase 3 studies later this year. Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: 'This investment reflects Jeito's commitment to accelerating the development of impactful therapies for patients with high unmet needs. Azafaros has the potential to develop new efficient, safe and tolerable therapeutic options for young patients suffering from progressive debilitating and even fatal rare metabolic disorders that generates very high expectations. We look forward to supporting the talented Azafaros team with our collective expertise to accelerate its pivotal clinical developments to go faster to patients.'Rachel Mears, Partner at Jeito Capital, added: 'Azafaros has been impressive in its execution with nizubaglustat poised to begin Phase 3 clinical development and the potential to significantly improve the lives of NPC and GM1/GM2 patients. We are excited to support and accelerate the Azafaros team in this important next step in the Company's clinical development journey. Leading this round further demonstrates Jeito's commitment to making a meaningful difference in patients' lives by pursuing much needed benefits for those suffering from rare diseases.' Stefano Portolano, Chief Executive Officer at Azafaros, concluded: 'This successful Series B round marks a significant milestone for Azafaros, allowing us to accelerate the development of nizubaglustat and leverage our scientific understanding and competencies to bring additional candidates into development. The fact that we have been able to attract leading life sciences investors to join our existing strong group of specialist investors is a testament to the impressive accomplishments of the team and the large unmet medical need that currently exists for patients with these hugely debilitating neurological diseases. We look forward to bringing nizubaglustat to patients.' About Jeito CapitalJeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito has built a diversified portfolio of clinical biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United more information, please visit or follow us on LinkedIn. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by Leading Healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. Contacts: Jeito Capital Rafaèle Tordjman, Founder & CEOJessica Fadel, EATel: +33 6 33 44 25 47 Maior ICR HealthcareStéphanie Elbaz Mary-Jane Elliott / Davide Salvi / Kris LamTel: +33 6 46 05 08 07 Jeito@ +44 (0) 20 3709 5700 Sean Leous ICR Healthcare Tel: +1 (646) 866 4012Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-03-2025
- Business
- Yahoo
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Investment will contribute to achieve clinical proof-of-concept for Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech). The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy. Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms. Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member. Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership. Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: 'We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. ' Rachel Mears, Parner at Jeito Capital added: 'Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. ' Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: 'We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.' About Jeito CapitalJeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United more information, please visit or follow us on LinkedIn or X. About Callio Therapeutics Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit and follow Callio Therapeutics on LinkedIn. Contacts:Jeito Capital Rafaèle Tordjman, Founder & CEOJessica Fadel, EATel: +33 6 33 44 25 47 MaiorStéphanie Elbaz – Tel: +33 6 46 05 08 07 ICR HealthcareMary-Jane Elliott / Davide Salvi / Kris LamJeito@ +44 (0) 20 3709 5700 1 EUR/USD exchange rate: 1 EUR = 1.0377 USD date February 7, 2025 (source: Banque de France)Sign in to access your portfolio
Associated Press
03-03-2025
- Business
- Associated Press
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Investment will contribute to achieve clinical proof-of-concept for Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech). The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy. Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms. Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member. Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership. Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: ' We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. ' Rachel Mears, Parner at Jeito Capital added: ' Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. ' Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: ' We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.' About Jeito Capital Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit or follow us on LinkedIn or X. About Callio Therapeutics Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit and follow Callio Therapeutics on LinkedIn. Contacts: Jeito Capital Rafaèle Tordjman, Founder & CEO Jessica Fadel, EA Tel: +33 6 33 44 25 47 Maior Stéphanie Elbaz – Tel: +33 6 46 05 08 07 ICR Healthcare Mary-Jane Elliott / Davide Salvi / Kris Lam
